Evidence map›Paper›PMID 25421283›Full record

ArticleNature reviews. Clinical oncology2015

Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery.

Qiang Gao, Xiao-Ying Wang, Jian Zhou, Jia Fan

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Nature reviews. Clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Single Large Nodule (>5 cm) Prognosis in Hepatocellular Carcinoma: Kinship with Barcelona Clinic Liver Cancer (BCLC) Stage A or B?Medical science monitor : international medical journal of experimental and clinical research · 2020
    Trial
  3. Review
  4. Article
  5. Article
  6. New concepts in the treatment of hepatocellular carcinoma.United European gastroenterology journal · 2022
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Qiang GaoLiver Cancer Institute and Zhongshan Hospital, Shanghai Medical School, Fudan University, 180 Fenglin Road, Shanghai 200032, People's Republic of China.
Xiao-Ying WangLiver Cancer Institute and Zhongshan Hospital, Shanghai Medical School, Fudan University, 180 Fenglin Road, Shanghai 200032, People's Republic of China.
Jian Zhou1] Liver Cancer Institute and Zhongshan Hospital, Shanghai Medical School, Fudan University, 180 Fenglin Road, Shanghai 200032, People's Republic of China. [2] Institute of Biomedical Sciences, Shanghai Medical School, Fudan University, 180 Fenglin Road, Shanghai 200032, People's Republic of China.
Jia Fan1] Liver Cancer Institute and Zhongshan Hospital, Shanghai Medical School, Fudan University, 180 Fenglin Road, Shanghai 200032, People's Republic of China. [2] Institute of Biomedical Sciences, Shanghai Medical School, Fudan University, 180 Fenglin Road, Shanghai 200032, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Chemoembolization, TherapeuticAntineoplastic AgentsCarcinoma, HepatocellularHumansLiver NeoplasmsAntineoplastic Agents

Identifiers

PMID25421283

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.